DrugPatentWatch Database Preview
Email this page to a colleagueSee Plans and Pricing
« Back to Dashboard
MEDI4736 is an investigational drug.
There have been 256 clinical trials for MEDI4736. The most recent clinical trial was a Phase 2 trial, which was initiated on September 6th 2019.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Carcinoma. The leading clinical trial sponsors are AstraZeneca, MedImmune LLC, and National Cancer Institute (NCI).
There are twenty-three US patents protecting this investigational drug and seven hundred and seventy-eight international patents.
Recent Clinical Trials for MEDI4736
|Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy||AstraZeneca||Phase 2|
|A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, the INSPIRE Study||National Cancer Institute (NCI)||Phase 2|
|DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma||AstraZeneca||Phase 3|
Top disease conditions for MEDI4736
Top clinical trial sponsors for MEDI4736
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|MEDI4736||Start Trial||Synergistic combination of immunologic inhibitors for the treatment of cancer||The University of Chicago (Chicago, IL)||Start Trial|
|MEDI4736||Start Trial||Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy||MedImmune Limited (Cambridge, GB)||Start Trial|
|MEDI4736||Start Trial||Heterocyclic modulators of lipid synthesis||3-V Biosciences, Inc. (Menlo Park, CA)||Start Trial|
|MEDI4736||Start Trial||Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer||AstraZeneca AB (Sodertalje, SE)||Start Trial|
|MEDI4736||Start Trial||Apilimod for use in the treatment of renal cancer||LAM Therapeutics, Inc. (Guilford, CT)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|MEDI4736||European Patent Office||2911669||2032-10-26||Start Trial|
|MEDI4736||World Intellectual Property Organization (WIPO)||2014066834||2032-10-26||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|